18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose of this study is to assess the utility of FDG PET/CT in evaluating response of bone dominant breast cancer to therapy. Eligible patients with bone dominant ER+ breast cancer will undergo baseline FDG PET/CT for evaluation of their disease, after the start of therapy they will undergo an FDG PET/CT scan at 4 weeks and again at 12 weeks. PET/CT results will be compared to clinical measures of response, time to progression and overall survival.
Condition or disease
Bone Dominant Metastatic ER+ Breast Cancer
Device: FDG PET/CTBiological: Fluorodeoxyglucose F 18 Injection (FDG)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A total of up to 75 subjects, age 18 years, with a diagnosis or estrogen receptor positive (ER+) breast cancer, with clinical evidence of bone dominant stage IV disease will be enrolled in this study. This study will enroll both women and men but it is anticipate that the majority of subjects will be women due to the small percentage of breast cancer patients that are male.
Adult patients, at least 18 years of age, with a history of pathologically confirmed ER+ breast cancer
Biopsy proven or clinically obvious documented bone metastases from breast cancer (with the majority of the disease burden in the bone)
Patients planning to start new endocrine targeted therapy (any line of therapy is acceptable and any endocrine therapy is allowed)
Willing and able to comply with scheduled visits and serial imaging procedures
Agrees to allow access to clinical records regarding response to treatment and long term follow up 6. Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines.
Women who are pregnant or breast feeding
Uncontrolled diabetes mellitus (fasting glucose greater than 200 mg/dL)
Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)
Weight exceeding capacity of imaging table
Previous treatment with radiation or surgery to a significant percentage of bony metastatic sites 6. Treatment with marrow stimulating agents (e.g. granulocyte colony stimulating factor (GCSF)) within 3 weeks of baseline scan